Payment overview · 2025
General Payments
$799.01
51 reported records · 19 companies
Healthcare provider profile · identity verified
Cody Robertson
Allopathic & Osteopathic Physicians|Family Medicine · NEWBERRY, SC · NPI 1225560675
Verified facts
What the public records show
CMS Open Payments records show Cody Robertson received $799.01 in general payments during 2025 across 51 reported records.
ABBVIE INC. accounted for 29.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Linzess by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $232.05 | 29.0% | 20 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.66 | 10.2% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $59.37 | 7.4% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $52.98 | 6.6% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.94 | 6.0% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.65 | 5.2% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.85 | 4.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.56 | 4.3% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $31.41 | 3.9% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $28.00 | 3.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.06 | 2.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $21.03 | 2.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.83 | 2.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.91 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.15 | 2.0% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $14.85 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.89 | 1.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.62 | 1.7% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $12.20 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $799.01 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $167.97 | 14 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.66 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $75.92 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $64.08 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $59.37 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $59.37 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $57.78 | 5 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $52.98 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $49.03 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $45.31 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $36.85 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.56 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $31.41 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.06 | 1 | 2025 |
Source payment records
|
|||||
| THORATEC HEARTMATE 3 LVAS IMPLANT KIT Normalized: thoratec heartmate 3 lvas implant kit |
Device | Abbott Laboratories | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.91 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.75 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $14.85 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $13.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| NEXPLANON Normalized: nexplanon |
Drug | Organon LLC | $12.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 42 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 67 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 102 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
42 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
67 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
102 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 294 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 257 | 72 |
| Omeprazole | Omeprazole | 204 | 54 |
| Losartan Potassium | Losartan Potassium | 182 | 51 |
| Gabapentin | Gabapentin | 173 | 53 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 42 |
| Tramadol Hcl | Tramadol Hcl | 121 | 31 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 36 |
| Metformin Hcl | Metformin Hcl | 115 | 31 |
| Lisinopril | Lisinopril | 114 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 111 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 26 |
| Levothyroxine Sodium | Levothyroxine Sodium | 102 | 25 |
| Ozempic | Semaglutide | 102 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 101 | 28 |
| Famotidine | Famotidine | 96 | 31 |
| Trazodone Hcl | Trazodone Hcl | 96 | 26 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 20 |
| Furosemide | Furosemide | 87 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 21 |
| Sertraline Hcl | Sertraline Hcl | 82 | 24 |
| Meloxicam | Meloxicam | 72 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 17 |
| Mounjaro | Tirzepatide | 67 | 15 |
| Chlorthalidone | Chlorthalidone | 65 | 18 |
| Metformin Hcl Er | Metformin Hcl | 63 | 19 |
| Carvedilol | Carvedilol | 60 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 55 | 21 |
| Simvastatin | Simvastatin | 52 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 12 |
| Montelukast Sodium | Montelukast Sodium | 45 | 11 |
| Lorazepam | Lorazepam | 43 | 14 |
| Jardiance | Empagliflozin | 42 | 15 |
| Bupropion Xl | Bupropion Hcl | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Allopurinol | Allopurinol | 36 | 12 |
| Prednisone | Prednisone | 34 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 34 | suppressed |
| Spironolactone | Spironolactone | 34 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 15 |
| Olanzapine | Olanzapine | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Alprazolam | Alprazolam | 30 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 30 | suppressed |
| Potassium Chloride | Potassium Chloride | 29 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Eliquis | Apixaban | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Clonazepam | Clonazepam | 21 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 20 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 16 |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Ondansetron Odt | Ondansetron | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 12 |
| Linzess | Linaclotide | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 13 | suppressed |
| Baclofen | Baclofen | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 12 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $799.01 · 51 records | ABBVIE INC. | Auvelity, BREZTRI, CAPLYTA, EVENITY, FANAPT, HETLIOZ, JARDIANCE, Kerendia, Korlym, MOUNJARO, NEXPLANON, NURTEC ODT, Ozempic, PROLIA, QULIPTA, REXULTI, Rybelsus, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, The Cologuard Plus Collection Kit, Tresiba, UBRELVY, VOQUEZNA, VRAYLAR, XIFAXAN, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error